aim
studi
explor
predict
implic
composit
immun
cell
popul
prior
lenalidomid
plu
highdos
dexamethason
lendex
initi
occurr
infect
prospect
examin
immun
cell
popul
peripher
blood
taken
baselin
lenalidomid
plu
lowdos
dexamethason
lendex
therapi
review
clinic
microbiolog
record
patient
refractoryrelaps
multipl
myeloma
rrmm
risk
factor
infect
analyz
use
logist
regress
median
cycl
lendex
treatment
patient
experienc
least
infect
episod
total
episod
infect
episod
clinic
defin
episod
microbiolog
defin
episod
fever
unknown
origin
sever
episod
frequent
observ
first
cycl
adjust
risk
factor
infect
base
univari
analys
multivari
analys
show
lower
hb
gdl
clinic
independ
factor
associ
occurr
infect
lower
frequenc
p
absolut
count
p
circul
cell
prior
lendex
treatment
also
associ
occurr
infect
especi
first
cycl
lendex
therapi
addit
sever
clinic
predict
factor
found
cell
may
provid
addit
inform
predict
occurr
infect
earli
period
lendex
therapi
multipl
myeloma
mm
clonal
plasma
cell
neoplasm
present
variabl
clinic
manifest
often
refer
crab
symptom
hypercalcemia
renal
insuffici
anemia
andor
bone
lesion
addit
crab
symptom
infect
lead
caus
morbid
mortal
mm
earli
death
attribut
infect
increas
risk
infect
seen
mm
due
diseaserel
immun
deficit
involv
humor
immun
variou
immun
system
compon
includ
cell
dendrit
cell
natur
killer
cell
treatmentrel
toxic
use
highdos
corticosteroid
therapi
also
increas
suscept
infect
larg
longitudin
cohort
studi
et
al
conduct
patient
mm
receiv
current
standard
treatment
proteasom
inhibitor
pi
immunemodulatori
drug
imid
autolog
stem
cell
transplant
reveal
highrisk
factor
infect
late
diseas
multipl
treatment
intens
combin
system
chemotherapi
corticosteroid
dose
despit
advanc
treatment
mm
mm
patient
nonetheless
ultim
relaps
becom
refractori
current
treatment
appropri
therapeut
option
patient
relapsedrefractori
mm
rrmm
remain
focu
research
treatment
paradigm
shift
use
small
biolog
molecul
pi
imid
hdac
inhibitor
effect
drug
immun
system
distinct
convent
antimyeloma
agent
result
chang
type
pattern
infect
particular
combin
lenalidomid
highdos
dexamethason
lendex
demonstr
efficaci
safeti
patient
relapsedrefractori
mm
two
larg
welldesign
pivot
clinic
trial
lenalidomid
plu
lowdos
dexamethason
lendex
led
better
overal
surviv
lower
toxic
lendex
patient
newli
diagnos
mm
also
remain
standard
care
relaps
refractori
set
therefor
analyz
pattern
risk
infect
patient
rrmm
lendex
treatment
sought
identifi
immun
cell
subtyp
relat
occurr
infect
use
multicolor
flow
cytometr
analysi
fresh
peripher
blood
mononuclear
cell
pbmc
isol
rrmm
patient
prior
lendex
initi
patient
rrmm
receiv
salvag
treatment
lendex
institut
elig
studi
therapi
regimen
consist
lenalidomid
mg
daili
oral
day
cycl
plu
lowdos
dexamethason
mg
per
day
weekli
dose
modif
perform
accord
recommend
thrombosi
prophylaxi
lowdos
aspirin
use
patient
antibacteri
prophylaxi
trimethoprimsulfamethoxazol
administ
prophylact
antifung
antivir
agent
use
identifi
novel
immun
cell
biomark
predict
infect
prospect
obtain
peripher
blood
sampl
baselin
prior
lendex
treatment
clinic
data
prospect
collect
time
lendex
initi
except
cytogenet
intern
stage
system
find
taken
data
establish
time
diagnosi
written
inform
consent
obtain
patient
particip
studi
studi
approv
institut
review
board
cathol
univers
korea
conduct
accord
declar
helsinki
blood
sampl
cell
popul
analysi
collect
immedi
lendex
initi
pbmc
isol
whole
blood
sampl
ml
collect
edtaco
tube
densiti
centrifug
use
ficollpaqu
pbmc
process
immedi
analysi
flow
cytometri
use
evalu
percentag
cell
natur
killer
nk
cell
myeloidderiv
suppressor
cell
mdsc
lin
hladr
granulocyt
hladr
monocyt
apc
isothiocyan
fitc
pe
monoclon
antibodi
mab
purchas
ebiosci
san
diego
ca
usa
antilineag
cocktail
lin
fitc
antihladrpercp
rat
antimous
mous
antihuman
bd
bioscienc
mab
purchas
bd
bioscienc
san
jose
ca
cell
gate
cell
express
percentag
lymphocyt
frequenc
hladr
lin
hladr
mdsc
express
percentag
total
pbmc
flow
cytometri
perform
use
fac
lsr
fortessa
bd
bioscienc
investig
infecti
complic
within
everi
cycl
cycl
day
lendex
treatment
data
period
analyz
infect
classifi
microbiolog
defin
clinic
defin
fever
unknown
origin
fuo
propos
immunocompromis
host
societi
infect
type
assess
accord
previou
report
sever
infect
grade
use
nation
cancer
institut
common
toxic
criteria
grade
scheme
grade
infect
defin
low
sever
grade
infect
high
sever
mortal
defin
infectionrel
death
without
refractori
progress
diseas
treatment
respons
assess
accord
criteria
intern
myeloma
work
group
imwg
studi
object
determin
infect
natur
includ
sever
type
time
well
clinic
predictor
infect
rrmm
patient
receiv
lendex
treatment
addit
predict
implic
composit
immun
cell
popul
prior
lendex
initi
explor
twotail
student
test
use
analyz
continu
variabl
two
group
potenti
risk
factor
occurr
infect
grade
first
cycl
rrmm
patient
receiv
lendex
treatment
assess
use
logist
regress
analysi
optim
cutoff
continu
variabl
identifi
use
receiv
oper
characterist
roc
curv
analysi
investig
whether
identifi
marker
independ
predictor
covari
p
valu
less
univari
analys
includ
multivari
analysi
total
rrmm
patient
men
women
median
age
year
rang
year
given
lendex
januari
februari
analyz
patient
characterist
summar
tabl
median
time
diagnosi
lendex
treatment
year
median
number
previou
treatment
line
receiv
two
previou
treatment
line
patient
previous
expos
bortezomib
patient
receiv
bortezomib
thalidomid
among
patient
undergon
prior
autolog
stem
cell
transplant
median
administ
cycl
number
rang
cycl
overal
respons
rate
good
partial
respons
greater
occur
patient
two
patient
evalu
one
lost
followup
discontinu
lendex
advers
event
evalu
median
followup
month
rang
month
survivor
median
progressionfre
surviv
overal
surviv
month
reach
respect
common
caus
discontinu
treatment
diseas
progress
follow
advers
event
tabl
patient
patient
least
episod
infect
grade
patient
episod
patient
episod
infect
high
sever
infect
grade
develop
patient
includ
patient
experienc
sever
infect
first
cycl
next
total
episod
infect
lendex
treatment
evalu
microbiolog
defin
clinic
defin
categor
fuo
microbiolog
defin
infect
bacteri
fungal
viral
origin
respect
variabl
pathogen
identifi
episod
bacteri
origin
includ
episod
caus
multipl
organ
escherichia
coli
n
asct
autolog
stem
cell
transplant
iflc
involv
free
light
chain
lendex
lenalidomid
lowdos
dexamethason
na
avail
ldh
lactat
dehydrogenas
highrisk
cytogenet
defin
hypodiploid
delet
convent
cytogenet
presenc
fluoresc
situ
hybrid
andor
convent
cytogenet
cytogenet
abnorm
consid
standard
risk
b
induct
asct
consid
one
therapeut
line
c
patient
measur
serum
protein
least
g
per
ml
includ
frequent
isol
organ
follow
pseudomona
aeruginosa
n
streptococcu
pneumonia
n
klebsiella
pneumonia
n
micrococcu
speci
n
staphylococcu
aureu
n
staphylococcu
homini
n
streptococcu
viridan
n
clostridium
difficil
n
acinetobact
baumannii
n
isol
microbiolog
defin
viral
infect
episod
episod
herp
zoster
episod
occur
due
rhinoviru
n
influenza
n
parainfluenza
n
coronaviru
n
one
episod
caus
pneumocysti
jirovecii
classifi
fungal
infect
respiratori
tract
n
common
site
infect
follow
skin
soft
tissu
infect
n
multipl
site
infect
n
also
frequent
observ
includ
bacteremia
n
major
episod
grade
sever
episod
high
sever
admiss
intens
care
unit
requir
infect
episod
two
infect
episod
result
death
characterist
episod
infect
describ
tabl
first
cycl
microbiolog
defin
infect
n
clinic
defin
infect
n
fuo
n
occur
fourteen
episod
infect
occur
first
cycl
high
sever
fig
longitudin
observ
epidemiolog
infect
rrmm
patient
receiv
lendex
treatment
observ
major
high
sever
infect
occur
first
cycl
accordingli
compar
frequenc
absolut
count
variou
immun
cell
popul
patient
develop
infect
grade
first
cycl
lendex
treatment
tabl
frequenc
cell
tend
decreas
baselin
p
p
cycl
therapi
respect
fig
frequenc
absolut
count
cell
lower
patient
develop
infect
grade
first
cycl
vs
p
frequenc
vs
p
absolut
count
patient
infect
grade
first
cycl
tend
lower
absolut
count
cell
vs
p
contrast
asct
autolog
stem
cell
transplant
cr
complet
respons
na
avail
pd
progress
diseas
pr
partial
respons
sd
stabl
diseas
vgpr
good
partial
respons
identifi
risk
factor
occurr
high
sever
infect
patient
evalu
clinic
myelomaassoci
variabl
univari
analys
supplementari
tabl
higher
level
serum
creatinin
mgdl
compar
mgdl
p
lower
level
hemoglobin
p
serum
albumin
p
associ
occurr
high
sever
infect
potenti
risk
factor
enter
multivari
logist
regress
model
immun
paramet
n
cl
ud
n
g
th
e
f
r
e
q
ue
nc
nd
bs
ol
ute
c
un
f
cell
absolut
count
cell
tabl
high
sever
infect
first
cycl
lendex
treatment
significantli
predict
lower
frequenc
rr
p
absolut
count
rr
p
cell
although
efficaci
toxic
lenalidomid
patient
rrmm
well
document
infect
remain
lead
complic
result
two
pivot
clinic
trial
found
incid
rate
infect
grade
approxim
patient
rrmm
receiv
lendex
although
use
lowdos
dexamethason
reduc
toxic
preserv
efficaci
lendex
kim
et
al
report
incid
rate
grade
febril
neutropenia
sepsi
pneumonia
respect
korean
patient
rrmm
dexamethason
mg
per
cycl
commonli
use
herein
demonstr
patient
experienc
least
infect
episod
lendex
treatment
sever
episod
frequent
observ
first
cycl
observ
increas
risk
infect
earli
treatment
period
consist
find
previou
studi
mani
studi
conduct
develop
novel
agent
demonstr
increas
risk
infect
earli
cours
particularli
within
month
follow
treatment
decreas
risk
infect
achiev
favor
respons
treatment
patient
mm
receiv
bortezomibbas
treatment
earli
cours
therapi
associ
develop
sever
bacteri
infect
addit
consid
diseaserel
treatmentrel
immun
deficit
patient
rrmm
explor
immun
cell
subset
associ
occurr
infect
order
evalu
emerg
potenti
cell
biomark
studi
lower
hb
gdl
clinic
independ
factor
associ
occurr
infect
lower
frequenc
p
absolut
count
p
cell
peripher
blood
prior
lendex
associ
occurr
infect
especi
first
cycl
lendex
therapi
recent
studi
report
increas
risk
infect
use
novel
agent
suggest
need
explor
relationship
kleber
et
al
show
uniqu
find
studi
suggest
immun
subtyp
predict
biomark
occurr
infect
especi
earli
period
therapi
type
ii
transmembran
glycoprotein
characterist
ctype
lectin
superfamili
receptor
express
nk
cell
adult
peripher
cell
peripher
blood
monocyt
vitroderiv
dendrit
cell
previous
evalu
associ
cell
develop
acut
graftversushost
diseas
agvhd
allogen
sct
found
low
proport
cell
high
ratio
cell
cell
peripher
blood
engraft
associ
occurr
agvhd
evid
higher
express
transcript
factor
cell
rather
cell
within
subset
express
associ
product
cell
doubleneg
cell
also
express
recent
agreement
receptor
nk
cell
play
inhibitori
role
wherea
role
cell
lack
consensu
recent
report
proport
pretranspl
circul
cell
allogen
stem
cell
transplant
set
associ
occurr
neutropen
inf
e
c
n
w
h
c
h
u
g
g
e
e
h
e
p
r
n
c
e
f
cell
rapid
immun
respons
microorgan
establish
posttranspl
immun
system
relat
pretranspl
cell
occurr
earli
complic
also
seen
autolog
stem
cell
transplant
set
studi
found
presenc
preexist
cell
may
play
import
role
decreas
risk
sever
infect
patient
rrmm
lendex
therapi
sever
studi
report
lymphopenia
marker
bacteri
infect
viral
fungal
infect
mm
patient
receiv
bortezomib
therapi
suggest
lymphopenia
indic
preexist
immunosuppress
condit
howev
data
immun
subtyp
predict
factor
infect
rrmm
patient
treat
lendex
evid
prophylact
use
antibiot
nonneutropen
mm
patient
still
inconclus
prophylact
antibiot
rais
concern
emerg
antibiot
resist
therefor
prophylact
use
antibiot
may
need
mm
patient
rather
patient
high
risk
occurr
infect
result
provid
use
inform
identifi
highrisk
patient
may
need
prophylact
use
antivir
antibiot
agent
especi
earli
treatment
cours
malign
conclus
found
patientand
treatmentrel
factor
affect
sever
type
time
infect
patient
rrmm
receiv
lendex
treatment
particular
lower
frequenc
absolut
count
cell
associ
occurr
infect
earli
period
lendex
therapi
take
account
risk
factor
occurr
infect
could
provid
signific
inform
guid
prophylact
use
antibiot
increas
monitor
develop
infect
lendex
treatment
